Year 2025 / Volume 117 / Number 5
Letter
Changing perspectives: unveiling the risks of ashwagandha-induced hepatotoxicity

288-289

DOI: 10.17235/reed.2023.10080/2023

Sergio Casiano-Manzano, Macarena Torres-Larrubia, Alberto Masa-Caballero, Zuliani Jiménez-Colmenarez, Elisa Martín-Noguerol, Miguel Fernández-Bermejo, Pablo Solís-Muñoz,

Abstract
Ashwagandha, an herb popular in Ayurvedic medicine, is renowned for its health-enhancing properties. However, its association with liver damage in recent years has raised significant concerns, necessitating careful assessment and management. This case underscores the dangers of Ashwagandha, particularly for individuals with preexisting liver conditions, where it can lead to life-threatening acute-on-chronic liver failure. The lack of solid clinical evidence supporting Ashwagandha's health claims emphasizes the need for an evidence-based approach. Public education is essential to raise awareness of the risks associated with herbal supplements and prevent liver diseases.
New comment
Comments
No comments for this article
References
(1) Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, et al. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clin Gastroenterol Hepatol. 2018;16(9):1495-1502. doi:10.1016/j.cgh.2017.12.051
(2) Andrade RJ, Aithal GP, Björnsson ES, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-1261. doi:10.1016/j.jhep.2019.02.014
(3) Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020;40(4):825-829. doi:10.1111/liv.14393
(4) Philips CA, Valsan A, Theruvath AH, et al. Ashwagandha-induced liver injury-A case series from India and literature review. Hepatol Commun. 2023;7(10):e0270. Published 2023 Sep 27. doi:10.1097/HC9.0000000000000270
(5) D'Cruz M, Andrade C. Potential clinical applications of Ashwagandha (Withania somnifera) in medicine and neuropsychiatry. Expert Rev Clin Pharmacol. 2022;15(9):1067-1080. doi:10.1080/17512433.2022.2121699
Related articles

Letter

Turmeric associated liver injury (DILI) with susceptible HLA

DOI: 10.17235/reed.2024.10763/2024

Editorial

Hemophilia and hepatology, back to the future

DOI: 10.17235/reed.2024.10105/2023

Letter

Cefditoren-induced hepatitis

DOI: 10.17235/reed.2022.8801/2022

Letter

Curcumin and curcumoids: hepatoprotection or hepatotoxicity?

DOI: 10.17235/reed.2022.8588/2022

Letter

Severe hepatotoxicity secondary to nintedanib

DOI: 10.17235/reed.2020.7585/2020

Case Report

Apixaban-induced liver injury

DOI: 10.17235/reed.2018.5877/2018

Letter to the Editor

Canalicular cholestasis induced by anabolic steroids

DOI: 10.17235/reed.2017.4781/2016

Citation tools
Casiano-Manzano S, Torres-Larrubia M, Masa-Caballero A, Jiménez-Colmenarez Z, Martín-Noguerol E, Fernández-Bermejo M, et all. Changing perspectives: unveiling the risks of ashwagandha-induced hepatotoxicity. 10080/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 36 visits.
This article has been downloaded 11 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 09/11/2023

Accepted: 15/11/2023

Online First: 20/11/2023

Published: 08/05/2025

Article Online First time: 11 days

Article editing time: 546 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology